Professor Simon Rule
Profiles

Professor Simon Rule

Professor in Haematology

Clinical Trials & Health Research - Institute of Translational & Stratified Medicine (Plymouth University Peninsula Schools of M

Qualifications

Bachelor of Medical Science with Honours 1984

Master of Philosophy 1986

Bachelor of Medicine 1987

Bachelor of Surgery 1987

Professional membership

Fellowof the Royal College of Physicians  2000

Fellowof the Royal College of Pathologists of  Australasia1994

Fellowof the Royal College of Pathologists 2006

Roles on external bodies

MemberNCRN Lymphoma Committee (2000 – 2005, 2006 -)

            Member Peninsula Comprehensive LocalResearch Network Board (2007  -)

            Member European Mantle Cell Lymphoma Network (2007 - )

            Member Peninsula Medical SchoolR&D committee (2010 -)

            Associate Medical Director forR&D Derriford Hospital (2010 - )

            Member Cancer Research UK ClinicalTrials Advisory Committee (2012 - )

MemberLeukaemia and Lymphoma Research Clinical Trials Committee (2012 -)

ChairNCRN Low Grade NHL Committee (2013 -)

Research interests

Clinical:

My clinical research is in non-Hodgkin’s lymphoma(NHL) and new drug development. Over the last 5 years I have been the ChiefInvestigator on 12 National studies and Principal Investigator on over 40 studiesmostly involving NHL.

I have a particular interest in mantle cellnon-Hodgkin’s lymphoma (MCL) and am regarded as the leading UK authority in thisdisease. I run a tertiary referral practice and see patients with this diseasereferred from all over the country in a weekly clinic. Within the UK I run allof the MCL trials. Over the last 10 years, 7 multi-centre trials have openedand 4 have recently completed. 4 of these studies were funded by Cancer ResearchUK, 2 others endorsed by CRUK and funded by industry The most recent studiesare coordinated and run through the Plymouth CTU. Two large studies will openin 2015. One is a large bio-bank funded by Leukaemia Lymphoma Researchexploring different disease characteristics of MCL. The other is a largerandomised trial funded by Cancer Research UK looking at the use of ibrutinibas front line therapy in elderly patients with MCL randomised against standardimmuno-chemotherapy. Both of these studies incorporate correlative science witha number of UK collaborators as well as in house laboratory research. Withbiological material stored in almost all patients this will be a uniquerepository for examining biological elements of the disease.

 

Laboratory:

 

My laboratory research is focussed on correlativescience associated with samples collected within clinical trials. Currently weare exploring the mechanism of action lenalidomide, an immuno-modulatory drugbased on a phase 2 single agent study run in Plymouth. Clinical responsescorrelate with changes in NK and T cell profiles and significant changes in arange of cytokines and chemokines. Gene expression analysis is currently beinganalysed on these samples. We have also described a new biomarker in thiscontext (serum free light chains). This work is now being translated in vitro using cell lines and exploringthe additional role of therapeutic antibodies to these agents. Lenalidomideaffects cellular membranes and alters CD 20 configuration as seen on con-focalmicroscopy. This has significance if the drug is given in combination with ananti-CD20 monoclonal antibody and this work is informing a planned combinationstudy. This has formed the basis of a recent PhD.

 

MCLis an aggressive form of non-Hodgkin’s lymphoma with an average survival of 3-4years. As such it is common practice to treat the disease at diagnosis with intensivetherapies. It has been my practice to observe patients at diagnosis who areasymptomatic and reserve treatment until symptoms evolve. A number of patientsexhibit extremely indolent disease behaviour with some patients untreated forover 5 years. We have obtained a local grant to perform gene expressionanalysis on our most indolent patients compared with patients requiringimmediate therapy. We observe a different gene expression signature which weare currently exploring further with the help of international collaborators.

Thenewer drugs that have activity in this disease (BTK, Pi3K and BCL-2 inhibitors)are being explored in the laboratory with cell line and patient samples with DrClare Hutchinson.  

 

 

Key publications are highlighted

Journals
Articles
Grigg A, Dyer MJS, Díaz MG, Dreyling M, Rule S, Lei G, Knapp A, Wassner-Fritsch E & Marlton P 2017 'Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma' Haematologica 102, (4) 765-772 , DOI PEARL
Rule S 2016 'A new standard of care for mantle cell lymphoma?' The Lancet Oncology 17, (1) 5-6 , DOI
Walter HS, Rule SA, Dyer MJS, Karlin L, Jones C, Cazin B, Quittet P, Shah N, Hutchinson CV & Honda H 2016 'A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies' Blood 127, (4) 411-419 , DOI
Rule S 2016 'Frontline therapy and role of high-dose consolidation in mantle cell lymphoma' Hematology 2016, (1) 419-424 , DOI
Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J & Bartlett NL 2016 'Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study' The Lancet Oncology 17, (2) 200-211 , DOI
Tucker DL & Rule SA 2016 'Ibrutinib for mantle cell lymphoma' Future Oncology 12, (4) 477-491 , DOI
Tucker DL, Naylor G, Kruger A, Hamilton MS, Follows G & Rule SA 2016 'Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom' British Journal of Haematology , DOI
Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, Offner F, Caballero D, Joao C & Witzens-Harig M 2016 'Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study' The Lancet 387, (10020) 770-778 , DOI
Trnený M, Lamy T, Walewski J, Belada D, Mayer J, Radford J, Jurczak W, Morschhauser F, Alexeeva J & Rule S 2016 'Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial' The Lancet Oncology 17, (3) 319-331 , DOI
Dreyling M, Ghielmini M, Rule S, Salles G, Vitolo U & Ladetto M 2016 'Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†' Annals of Oncology 27, (suppl_5) v83-v90 , DOI
Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, Rule S, Advani R, Iberri D & Phillips T 2016 'Postibrutinib outcomes in patients with mantle cell lymphoma' Blood 127, (12) 1559-1563 , DOI
Tucker DL, Mihailescu L, Riordan R & Rule S 2016 'Remineralization of lytic bone disease in a patient with small lymphocytic lymphoma using ibrutinib' British Journal of Haematology , DOI
Rule S, Smith P, Johnson PWM, Bolam S, Follows G, Gambell J, Hillmen P, Jack A, Johnson S & Kirkwood AA 2016 'The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial' Haematologica 101, (2) 235-240 , DOI
Furtado M, Clarke K, Medd P, Hunter H & Rule S 2016 'The use of Bruton's tyrosine kinase inhibition as a bridging strategy to successful allogeneic stem cell transplant in relapsed mantle cell lymphoma' Leukemia & Lymphoma 57, (2) 461-462 , DOI
Furtado M, Johnson R, Kruger A, Turner D & Rule S 2015 'Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma' British Journal of Haematology 168, (1) 55-62 , DOI
Tucker DL, Rockett M, Hasan M, Poplar S & Rule SA 2015 'Does transcutaneous electrical nerve stimulation (TENS) alleviate the pain experienced during bone marrow sampling in addition to standard techniques? A randomised, double-blinded, controlled trial' Journal of Clinical Pathology 68, (6) 479-483 , DOI
Jones GL, Will A, Jackson GH, Webb NJ & Rule S 2015 'Evolving concepts in tumour lysis syndrome management - response to Ayed et al' British Journal of Haematology 173, (3) 486-487 , DOI
Jones GL, Will A, Jackson GH, Webb NJA & Rule S 2015 'Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology' British Journal of Haematology 169, (5) 661-671 , DOI
Shah N, Tam C, Seymour JF & Rule S 2015 'How applicable is fludarabine, cyclophosphamide and rituximab to the elderly?' Leukemia & Lymphoma 56, (6) 1599-1610 , DOI
Cramer P, Chanan-Khan A, Fraser G, Demirkan F, Silva RS, Pylypenko H, Grosicki S, Janssens A, Pristupa A & Goy A 2015 'Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): safety analysis in the HELIOS trial' LEUKEMIA & LYMPHOMA 56, 93-94 Author Site
Fraser G, Chanan-Khan A, Cramer P, Demirkan F, Silva RS, Pylypenko H, Grosicki S, Janssens A, Pristupa A & Goy A 2015 'Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): subgroup efficacy analyses from the HELIOS trial' LEUKEMIA & LYMPHOMA 56, 98-100 Author Site
Chanan-Khan A, Fraser G, Cramer P, Demirkan F, Silva RS, Pylypenko H, Grosicki S, Janssens A, Pristupa A & Goy A 2015 'Ibrutinib combined with bendamustine/rituximab (BR) in previously treated small lymphocytic lymphoma (SLL): analysis of patients in the HELIOS trial' LEUKEMIA & LYMPHOMA 56, 92-93 Author Site
Rule S, Goy A, Martin P, Ramchandren R, Alexeeva J, Popat R, Avivi I, Advani R, Le Gouill S & Horowitz N 2015 'IBRUTINIB FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL): EVALUATING THE CORRELATION BETWEEN PATIENT-REPORTED OUTCOMES AND DURABILITY OF RESPONSE IN A PHASE 2 STUDY' VALUE IN HEALTH 18, (3) A300-A301 Author Site
Furtado M, Wang ML, Munneke B, McGreivy J, Beaupre DM & Rule S 2015 'Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma' British Journal of Haematology 170, (1) 131-134 , DOI
Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE & Williams ME 2015 'Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results' Blood 126, (6) 739-745 , DOI
Dreyling M, Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH & Romaguera JE 2015 'Long-term safety and efficacy of single-agent lbrutinib in patients with relapsed or refractory mantle cell lymphoma: Updated results of an international, multicenter, open-label phase 2 study' Oncology Research and Treatment 38, 18-19 Author Site
Campo E & Rule S 2015 'Mantle cell lymphoma: evolving management strategies' Blood 125, (1) 48-55 , DOI
Rule S 2015 'Response to the letter from Gozzetti et al. entitled: “Oral low-dose fludarabine and cyclophosphamide with rituximab as initial treatment for elderly patients with chronic lymphoproliferative disorders”' Leukemia & Lymphoma 56, (6) 1918-1918 , DOI
Robinson S, Dreger P, Caballero D, Corradini P, Geisler C, Ghielmini M, Le Gouill S, Kimby E, Rule S & Vitolo U 2015 'The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma' Leukemia 29, (2) 464-473 , DOI
Dreyling M, Amador V, Callanan M, Jerkeman M, Le Gouill S, Pott C, Rule S & Zaja F 2015 'Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network' Leukemia & Lymphoma 56, (4) 866-876 , DOI
Shah N, Hutchinson C & Rule S 2014 'Ibrutinib for the treatment of mantle cell lymphoma' Expert Review of Hematology 7, (5) 521-531 , DOI
Balasubramanian S, Schaffer M, Deraedt W, Davis C, Stepanchick E, Aquino R, Yuan Z, Kranenburg B, Avivi I & Dreyling M 2014 'Mutational Analysis of Patients with Primary Resistance to Single-Agent Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)' BLOOD 124, (21) Author Site
Dreyling M, Geisler C, Hermine O, Kluin-Nelemans HC, Le Gouill S, Rule S, Shpilberg O, Walewski J & Ladetto M 2014 'Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up' Annals of Oncology 25, (suppl 3) iii83-iii92 , DOI
Furtado M, Dyer MJS, Johnson R, Berrow M & Rule S 2014 'Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma - a phase II trial' British Journal of Haematology 165, (4) 575-578 , DOI
Rule S, Briones J, Smith R, Theodore OC, Ngoh CA, Osborne S, Capochiani E & Rummel M 2014 'Preference for Rituximab Subcutaneous (Sc) and Intravenous (Iv) Among Patients With Cd20+ Non-Hodgkin's Lymphoma (Nhl) Completing the Rasq Measure In Randomized Phase Iii Studies Prefmab and Mabcute' Value in Health 17, (7) A537-A537 , DOI
Wang M, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani R, Romaguera JE & Williams ME 2014 'Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study' BLOOD 124, (21) Author Site
Rule S, Collins GP & Samanta K 2014 'Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom' Journal of Medical Economics 17, (7) 459-468 , DOI
Stilgenbauer S, Rule S, Wang ML, Martin P, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera J & Williams M 2014 'Updated phase 2 safety analysis of prevalence of infection, diarrhea, and bleeding with ibrutinib over time in previously treated mantle cell lymphoma' ONCOLOGY RESEARCH AND TREATMENT 37, 34-35 Author Site
Furtado M, Shah N, Levoguer A, Harding S & Rule S 2013 'Abnormal serum free light chain ratio predicts poor overall survival in mantle cell lymphoma' Br J Haematol 160, (1) 63-69 Author Site , DOI
Burt C, Roddari J, Mindos T, Furtado M, Rule S & McCallum L 2013 'CCN1 modulates cell growth in aggressive mantle cell lymphoma' BRITISH JOURNAL OF HAEMATOLOGY 161, 44-44 Author Site
Shah N, Furtado M, Eve H & Rule S 2013 'Natural killer cells and their clinical correlation in mantle cell lymphoma (MCL)' BRITISH JOURNAL OF HAEMATOLOGY 161, 55-55 Author Site
Coiffier B, Li W, Henitz ED, Karkera JD, Favis R, Gaffney D, Shapiro A, Theocharous P, Elsayed YA & van de Velde H 2013 'Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab' Clin Cancer Res 19, (9) 2551-2561 Author Site , DOI
Leblond V, Johnson S, Chevret S, Copplestone A, Rule S, Tournilhac O, Seymour JF, Patmore RD, Wright D & Morel P 2013 'Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma' J Clin Oncol 31, (3) 301-307 Author Site , DOI
Wang ML, Rule SAJ, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Ranjana H & Romaquera JE 2013 'Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma' New England Journal of Medicine 369, (6) 507-516 , DOI
Rule S, Furtado M, Eve H, Johnson R, Kruger A, Turner D & Bullard S 2013 'The addition of bortezomib to standard dose CHOP chemotherapy significantly improves survival in relapsed mantle cell lymphoma - final analysis of a randomised UK NCRN trial' BRITISH JOURNAL OF HAEMATOLOGY 161, 5-5 Author Site
Wright TM, Rule S, Liu H, Du M-Q & Smith MEF 2012 'Extranodal marginal zone lymphoma of the uterine corpus' LEUKEMIA & LYMPHOMA 53, (9) 1831-1834 Author Site , DOI
McKay P, Leach M, Jackson R, Cook G & Rule S 2012 'Guidelines for the investigation and management of mantle cell lymphoma' BRITISH JOURNAL OF HAEMATOLOGY 159, (4) 405-426 Author Site , DOI
Farrell K & Rule S 2012 'Mantle-cell lymphoma in the elderly: is it time to CHOP and change?' Leukemia & Lymphoma 53, (10) 1855-1856 , DOI
Eve HE, Carey S, Richardson SJ, Heise CC, Mamidipudi V, Shi T, Radford JA, Auer RL, Bullard SH & Rule SAJ 2012 'Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences' British Journal of Haematology 159, (2) 154-163 , DOI
Eve HE, Carey S, Helse CC, Richardson SJ, Mamidipudi V, Shi T, Radford JA, Auer RL, Bullard SH & Rule SA 2012 'Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences' British Journal of Haematology 159, (2) 154-163 , DOI
Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, Rule S, Teixeira A, Walewski J & de Vos S 2011 'Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial' LANCET ONCOLOGY 12, (8) 773-784 Author Site , DOI
Hellmann A, Rule S, Walewski J, Shpilberg O, Feng H, van de Velde H, Patel H, Skee DM, Girgis S & Louw VJ 2011 'Effect of Cytochrome P450 3A4 Inducers on the Pharmacokinetic, Pharmacodynamic and Safety Profiles of Bortezomib in Patients with Multiple Myeloma or Non-Hodgkinʼs Lymphoma' Clinical Pharmacokinetics 50, (12) 781-791 , DOI
Furtado M & Rule S 2011 'Indolent mantle cell lymphoma' HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 96, (8) 1086-1088 Author Site , DOI
Rule SAJ, Poplar S, Evans PAS, O'Connor SJM & Owen RG 2011 'Indolent Mantle-Cell Lymphoma: Immunoglobulin Variable Region Heavy Chain Sequence Analysis Reveals Evidence of Disease 10 Years Prior to Symptomatic Clinical Presentation' Journal of Clinical Oncology 29, (15) e437-e439 , DOI
Dreyling M, Kluin-Nelemans HC, Bea S, Hartmann E, Salaverria I, Hutter G, Perez-Galan P, Roue G, Pott C & Le Gouill S 2011 'Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network' LEUKEMIA & LYMPHOMA 52, (12) 2226-2236 Author Site , DOI
Rule S 2011 'Velcade combinations in mantle cell lymphoma: are we learning anything?' Leuk Lymphoma 52, (4) 545-547 Author Site , DOI
Richardson SJ, Eve HE, Copplestone JA, Dyer MJ & Rule SAJ 2010 'Activity of thalidomide and lenalidomide in mantle cell lymphoma' Acta Haematol 123, (1) 21-29 Author Site , DOI
Eve HE & Rule SAJ 2010 'Autoimmune haemolytic anaemia associated with mantle cell lymphoma' International Journal of Hematology 91, (2) 322-325 , DOI
Rule S 2010 'Everolimus in relapsed Hodgkin's lymphoma: something exciting or a case of caveat mTOR?' Am J Hematol 85, (5) 313-314 Author Site , DOI
Matthey F, Parker A, Rule SAJ, Wimperis JZ, Ardeshna KM, Bird JM, Cullis J, Lyttelton MPA, McMillan A & Jackson GH 2010 'Facilities for the treatment of adults with haematological malignancies – 'Levels of Care': BCSH Haemato-Oncology Task Force 2009' Hematology 15, (2) 63-69 , DOI
Eve HE & Rule SAJ 2010 'Lenalidomide-induced tumour flare reaction in mantle cell lymphoma' British Journal of Haematology 151, (4) 410-412 , DOI
Cook G, Smith GM, Kirkland K, Lee J, Pearce R, Thomson K, Morris E, Orchard K, Rule S & Russell N 2010 'Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study of the British Society for Blood and Marrow Transplantation' BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 16, (10) 1419-1427 Author Site , DOI
Agathocleous A, Rohatiner A, Rule S, Hunter H, Kerr JP, Neeson SM, Matthews J, Strauss S, Montoto S & Johnson P 2010 'Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia' Br J Haematol 151, (4) 346-353 Author Site , DOI
Rule S, Smith P, Qian W, Gambell J, Curtis N, Johnson P & Linch D 2009 'Application of the mantle international prognostic index (MIPI) to patients with mantle cell lymphoma treated with fludarabine/cyclophosphamide: Results from a UK NCRI Lymphoma Group study' J Clin Oncol 27, (15_suppl) Author Site
Pace E, Dennison S, Morris J, Barton A, Pritchard C & Rule SAJ 2009 'Chemotherapy in the community: what do patients want?' Eur J Cancer Care (Engl) 18, (2) 209-215 Author Site , DOI
Eve HE, Seymour JF & Rule SAJ 2009 'Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamide±rituximab' Leukemia & Lymphoma 50, (3) 463-465 , DOI
Eve HE, Gambell J, Smith P, Qian W & Rule SAJ 2009 'The simplified mantle cell lymphoma international prognostic index predicts overall survival but not progression-free survival in patients with mantle cell lymphoma treated with fludarabine and cyclophosphamide±rituximab: results of a randomized phase II trial' Leukemia & Lymphoma 50, (10) 1709-1711 , DOI
Eve HE, Furtado MV, Hamon MD & Rule SAJ 2009 'Time to Treatment Does Not Influence Overall Survival in Newly Diagnosed Mantle-Cell Lymphoma' Journal of Clinical Oncology 27, (32) e189-e190 , DOI
Eve HE, Linch D, Qian W, Ross M, Seymour JF, Smith P, Stevens L & Rule SAJ 2009 'Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study' Leukemia & Lymphoma 50, (2) 211-215 , DOI
Furtado MV & Rule SAJ 2009 'Validation of the mantle cell lymphoma international prognostic index (MIPI) in a non selected population of patients' BRITISH JOURNAL OF HAEMATOLOGY 145, 14-14 Author Site
Furtado M & Rule S 2008 'Bortezomib-associated tumor lysis syndrome in multiple myeloma' LEUKEMIA & LYMPHOMA 49, (12) 2380-2382 Author Site , DOI
Sleigh KA, Smith MEF & Rule SAJ 2008 'Cardiac involvement with mycosis fungoides: Could this explain alemtuzumab toxicity?' Leukemia & Lymphoma 49, (10) 2022-2024 , DOI
Morschhauser F, Illidge T, Huglo D, Martinelli G, Paganelli G, Zinzani PL, Rule S, Liberati AM, Milpied N & Hess G 2007 'Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphorna not appropriate for autologous stem-cell transplantation' BLOOD 110, (1) 54-58 Author Site , DOI
Richardson SJ, Widmer M, Zajicek J & Rule SA 2007 'Physiological doses of cannabinoids do not adversely affect MCL viability' Leukemia & Lymphoma 48, (9) 1855-1857 , DOI
Pettengell R, Donatti C, Hoskin P, Poynton C, Kettle PJ, Hancock B, Johnson S, Dyer MJS, Rule S & Walker M 2007 'The impact of follicular lymphoma on health-related quality of life' Annals of Oncology 19, (3) 570-576 , DOI
Dasgupta RK, Rule S, Johnson P, Davies J, Burnett A, Poynton C, Wilson K, Smith GM, Jackson G & Richardson C 2006 'Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect' Bone Marrow Transplant 37, (5) 455-461 Author Site , DOI
Cherian G, Thomas DW & Rule SAJ 2006 'The efficacy of low dose thalidomide in refractory/relapsed myeloma—a retrospective audit' Leukemia & Lymphoma 47, (11) 2409-2411 , DOI
Harries LW, Wickham CL, Evans JC, Rule SA, Joyner MV & Ellard S 2005 'Analysis of haematopoietic chimaerism by quantitative real-time polymerase chain reaction' Bone Marrow Transplantation 35, (3) 283-290 , DOI
Thomas DW, Owen RG, Johnson SAN, Hillmen P, Seymour JF, Wolf MM & Rule SAJ 2005 'Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP' Leukemia & Lymphoma 46, (4) 549-552 , DOI
Snowden JA, Passweg J, Moore JJ, Milliken S, Cannell P, Van Laar JM, Verburg R, Szer J, Taylor K & Joske D 2004 'Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: A report from the EBMT and ABMTR' JOURNAL OF RHEUMATOLOGY 31, (3) 482-488 Author Site
Rule S 2004 'Managing cancer-related skeletal events with bisphosphonates' Hosp Med 65, (6) 355-360 Author Site
Rule S & Copplestone A 2003 'Ethics of large clinical trials in rapidly lethal diseases' LANCET 361, (9365) 1297-1297 Author Site , DOI
Pagliuca A, Carrington PA, Pettengell R, Rule S, Keidan J & Haematology BCS 2003 'Guidelines on the use of colony-stimulating factors in haematological malignancies' BRITISH JOURNAL OF HAEMATOLOGY 123, (1) 22-33 Author Site , DOI
Duckworth AW & Rule SAJ 2003 'The use of 'touchdown' polymerase chain reaction increases the sensitivity and specificity of t(11;14)(q13;q32) detection in patients with mantle cell lymphoma' British Journal of Haematology 121, (6) 952-953 , DOI
Moore J, Brooks P, Milliken S, Biggs J, Ma D, Handel M, Cannell P, Will R, Rule S & Joske D 2002 'A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis' Arthritis & Rheumatism 46, (9) 2301-2309 , DOI
Monk SE, Duckworth AW, Farrugia J, Copplestone JA & Rule SAJ 2002 'Allelic discrimination of factor V Leiden using the GeneAmp (R) 5700 Sequence Detection System' THROMBOSIS AND HAEMOSTASIS 88, (6) 1071-1072 Author Site
Rule SAJ 2002 'Managing cutaneous reactions to imatinib therapy' Blood 100, (9) 3434-3434 , DOI
O'Brien SG & Rule SAJ 2002 'Position paper on imatinib mesylate in chronic myeloid leukaemia*' British Journal of Haematology 119, (1) 268-272 , DOI
Rule S, Poirer V & Singer C 2001 'Management of acute myeloid leukaemia: A Regional Audit in the South and West of the United Kingdom' Clinical Medicine 1, (4) 313-316 , DOI
Rule S 2001 'Non-Hodgkin's lymphoma' Clin Med (Lond) 1, (5) 362-364 Author Site
Savage DG, I Rule SA, Tighe M, Garrett TJ, Oster WM, Lee RT, Ruiz J, Heitjan D, Keohan ML & Flamm M 2000 'Gemcitabine for relapsed or resistant lymphoma' Annals of Oncology 11, (5) 595-597 , DOI
FREWIN REBECCA, TURNER DEBORAH, TIGHE MARY, DAVIES SIMON, RULE SIMON & JOHNSON STEPHEN 1999 'Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders' British Journal of Haematology 104, (3) 612-613 , DOI
Pawson R, Davies J, McQuillan A, Rule S, Joske D, Spagnolo D & Erber W 1999 'Immunophenotyping by flow cytometry of bone marrow but not peripheral blood is useful in staging of Non-Hodgkin's Lymphomas' BLOOD 94, (10) 252B-252B Author Site
Cunningham LM, Dunstan R, Joske DJ & Rule S 1999 'Interleukin 10 promoter polymorphisms in Hodgkin's and non-Hodgkin's lymphoma' BLOOD 94, (10) 244B-244B Author Site
Tomlinson J, Tighe M, Johnson S, Stone R, Nicholson AG & Rule S 1999 'Interstitial Pneumonitis Following Mitozantrone, Chlorambucil and Prednisolone (MCP) Chemotherapy' Clinical Oncology 11, (3) 184-186 , DOI
Rule S, McQuillan A, Pawson R, Davies J, Thomas W, Johnson S, Joske D & Erber W 1999 'Non-cryopreserved stem cells for transplantation in patients with multiple myeloma' BLOOD 94, (10) 341B-341B Author Site
Turner DL, Johnson SA & Rule SA 1999 'Successful treatment of candidal osteomyelitis with fluconazole following failure with liposomal amphotericin B' Journal of Infection 38, (1) 51-53 , DOI
Rule S, Poirier V & Singer CRJ 1999 'The investigation and management of patients with acute myeloblastic leukaemia in the South & West Region of the United Kingdom National Health Service' BLOOD 94, (10) 186A-186A Author Site
Pawson R, Davies J, Moy M, Spagnolo D, Joske D & Rule S 1999 'Value of flow cytometry on lymph nodes and extranodal tissue samples in the diagnosis of patients with suspected Non-Hodgkin's Lymphoma' BLOOD 94, (10) 252B-252B Author Site
Frewin R, Turner D, Tighe M, Davies S, Rule S & Johnson S 1998 'Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders' BRITISH JOURNAL OF HAEMATOLOGY 101, 40-40 Author Site
Child JA, Morgan GJ, Smith GM, Johnson SAN, Rule S, Johnson PWM, Prentice AG & Tollerfield SM 1998 'FluDAP as pre-autograft chemotherapy for recurrent/refractory non-Hodgkin's lymphoma' BRITISH JOURNAL OF HAEMATOLOGY 102, (1) 235-235 Author Site
Rohatiner AZS, Bassan R, Bjorkholm M, Rule S, Newland AC, Raimondi R, Carter M & Lister TA 1998 'High-dose treatment (HDT) with peripheral blood progenitor cell (PBPC) support as consolidation of first remission in younger patients (Pts.) with acute myelogenous leukaemia (AML)' BLOOD 92, (10) 293A-293A Author Site
Bromidge TJ, Turner DL, Howe DJ, Johnson SA & Rule SAJ 1998 'In vitro chemosensitivity of chronic lymphocytic leukaemia to purine analogues – correlation with clinical course' Leukemia 12, (8) 1230-1235 , DOI
Turner D, Tighe M, Johnson S, Davies SV, Phillips MJ, Frewin R & Rule S 1998 'Mitozantrone, chlorambucil and prednisolone (MCP) in the treatment of elderly patients with high grade non-Hodgkin's lymphoma' BRITISH JOURNAL OF HAEMATOLOGY 102, (1) 242-242 Author Site
Rule S, Tighe M, Davies S & Johnson S 1998 'Vinorelbine in the treatment of lymphoma' HEMATOLOGICAL ONCOLOGY 16, (3) 101-105 Author Site , DOI
Dokal I, Rule S, Chen F, Potter M & Goldman J 1997 'Adult onset of acute myeloid leukaemia (M6) in patients with Shwachman-Diamond syndrome' British Journal of Haematology 99, (1) 171-173 , DOI
Bromidge TJ, Howe DJ, Johnson SA & Rule SA 1997 'Heterogeneity of clonal lymphocytes with regard to bcl-2 protein concentration and cell size' Molecular Pathology 50, (6) 326-328 , DOI
Savage DG, Taylor P, Blackwell J, Chen F, Szydlo RM, Rule SAJ, Spencer A, Apperley JF & Goldman JM 1997 'Paranasal sinusitis following allogeneic bone marrow transplant' Bone Marrow Transplantation 19, (1) 55-59 , DOI
Jager HR, Williams EJ, Savage DG, Rule SAJ, Hajnal JV, Sikora K, Goldman JM & Bydder GM 1996 'Assessment of brain changes with registered MR before and after bone marrow transplantation for chronic myeloid leukemia' AMERICAN JOURNAL OF NEURORADIOLOGY 17, (7) 1275-1282 Author Site
OBrien SG, Spencer A, Rule S, Hawkins T, Savage D, Apperley JF, Chase AJ, McDonald C, Davidson RJ & Goldman JM 1996 'Chronic phase CML autografting using PBPCs mobilised by intermediate-dose chemotherapy - An update of the Hammersmith experience' BRITISH JOURNAL OF HAEMATOLOGY 93, 278-278 Author Site
OBrien SG, Spencer A, Rule S, Hawkins T, Savage D, Apperley JF, Chase AJ, McDonald C, Davidson RJ & Goldman JM 1996 'Chronic phase cml autografting using PBPCs mobilised by intermediate-dose chemotherapy an update of the Hammersmith experienc' BRITISH JOURNAL OF HAEMATOLOGY 93, 4-4 Author Site
Howe D, Bromidge T, Johnson S & Rule S 1996 'Dynamics of trisomy 12 clones before and during chemotherapy' BRITISH JOURNAL OF HAEMATOLOGY 93, 1078-1078 Author Site
OBrien SG, Apperley JF, Szydlo R, Spencer A, Rule SA, Savage D, Blackwell J, Orchard K, Chase A & Hawkins TE 1996 'High dose busulfan alone as cytoreduction before autografting for chronic myeloid leukemia - A feasibility study' BLOOD 88, (10) 3528-3528 Author Site
Rule SAJ, Savage DG, O'Brien SG, Orchard K, McDonald C, Davidson J, Matthey F, Reilly JT, Bardhan G & Miller E 1996 'Intermediate-dose busulphan before autografting for advanced-phase chronic myeloid leukaemia' British Journal of Haematology 94, (4) 694-698 , DOI
Rohatiner AZS, Bassan R, Bjorkholm M, Rule S, Newland A, Apostolidis J & Raymondi R 1996 'Myeloablative therapy with peripheral blood progenitor cell (PBPC) support as consolidation of first remission in younger patients with acute myelogenous Leukaemia (AML)' BRITISH JOURNAL OF HAEMATOLOGY 93, 849-849 Author Site
Sill H, Rule SAJ, Joske DJL, Chase A, Lin F, Goldman JM & Cross NCP 1996 'Reconstitution with Philadelphia chromosome-negative recipient haematopoiesis early after allogeneic BMT for CML' BONE MARROW TRANSPLANTATION 17, (3) 453-455 Author Site
Grubb H, Rule S & Johnson S 1996 'Treatment of Waldenstrom's Macroglobulinaemia with fludarabine. Results in 7 patients with long term follow up' BRITISH JOURNAL OF HAEMATOLOGY 93, 277-277 Author Site
Rule S, Tighe M & Johnson S 1996 'Vinorelbine (Navelbine) an active agent in the salvage of heavily pre-treated patients with Hodgkin's and non-Hodgkin's lymphoma' BRITISH JOURNAL OF HAEMATOLOGY 93, 1402-1402 Author Site
Forbes GM, Rule SAJ, Herrmann RP, Davies JM & Collins BJ 1995 'A prospective study of screening upper gastrointestinal (GI) endoscopy prior to and after bone marrow transplantation (BMT)' Australian and New Zealand Journal of Medicine 25, (1) 32-36 , DOI
OBRIEN SG, GEWIRTZ AM, RULE SA, HAWKINS TE, RATAJCZAK MZ, SAVAGE D, LUGER SM & GOLDMAN JM 1995 'AUTOGRAFTING FOR CML USING BONE-MARROW PURGED WITH MYB ANTISENSE OLIGONUCLEOTIDE' EXPERIMENTAL HEMATOLOGY 23, (8) 804-804 Author Site
RULE SAJ, OBRIEN SG, SPENCER A, APPERLEY J & GOLDMAN JM 1995 'BONE-MARROW TRANSPLANTATION - REVIEW ARTICLES MUST ACCURATELY REFLECT CURRENT PRACTICE' BRITISH MEDICAL JOURNAL 310, (6983) 874-874 Author Site
SPENCER A, SZYDLO RM, BROOKES PA, KAMINSKI E, RULE S, VANRHEE F, WARD KN, HALE G, WALDMANN H & HOWS JM 1995 'BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA WITH VOLUNTEER UNRELATED DONORS USING EX-VIVO OR IN-VIVO T-CELL DEPLETION - MAJOR PROGNOSTIC IMPACT OF HLA CLASS-I IDENTITY BETWEEN DONOR AND RECIPIENT' BLOOD 86, (9) 3590-3597 Author Site
Rule SAJ, Erber WN, Lown JAG, Dale BJ, Herrmann RP & Davies JM 1994 'Cross-Matched Platelets In Bone Marrow Transplantation' Pathology 26, (3) 288-290 , DOI
RULE S & DAVIES J 1994 'Intermittent dosing of granulocyte colony stimulating factor (G-CSF) to facilitate palliative radiotherapy' Australian and New Zealand Journal of Medicine 24, (4) 402-402 , DOI
Rule SAJ, Hooker M, Costello C, Luck W & Hoffbrand AV 1994 'Serum vitamin B12 and transcobalamin levels in early HIV disease' American Journal of Hematology 47, (3) 167-171 , DOI
Erber WN, Asbahr H, Rule SA & Scott CS 1994 'Unique immunophenotype of acute promyelocytic leukaemia as defined by CD9 and CD68 antibodies' British Journal of Haematology 88, (1) 101-104 , DOI
PERRETT K 1993 'Epoetin in elective hip replacement' The Lancet 341, (8861) 1665-1665 , DOI
RULE SAJ, COSTELLO C, WATERHOUSE P & RETSAS S 1993 'PARANEOPLASTIC EOSINOPHILIA IN MALIGNANT-MELANOMA' JOURNAL OF THE ROYAL SOCIETY OF MEDICINE 86, (5) 295-295 Author Site
HERRMANN RP, RULE SAJ, DAVIES JM & LEATHER HL 1993 'SUBSTITUTION OF CARBOPLATIN FOR CISPLATIN IN THE DHAP (PARMA) REGIMEN IS EFFECTIVE SALVAGE THERAPY IN RELAPSED LYMPHOMA' EXPERIMENTAL HEMATOLOGY 21, (8) 1124-1124 Author Site
Rule S, Brooksby P & Sanderson J 1993 'Use of thrombolysis for acute myocardial infarction by general practitioners' Postgraduate Medical Journal 69, (809) 190-193 , DOI
Costello C, Rule S, Shanson D & Mir N 1992 'Bone-marrow diagnosis of opportunistic infections in HIV disease' AIDS 6, (12) 1559-1560 , DOI
Rule S, Reed C & Costello C 1991 'FATAL HAEMOPHAGOCYTIC SYNDROMES IN HIV-ANTIBODY POSITIVE PATIENT' British Journal of Haematology 79, (1) 127-127 , DOI
Whelan JS, Davis CL, Rule S, Ranson M, Smith OP, Mehta AB, Catovsky D, Rohatiner AZS & Lister TA 1991 'Fludarabine phosphate for the treatment of low grade lymphoid malignancy' British Journal of Cancer 64, (1) 120-123 , DOI
McCarthy D, Samson D, Mir N, Rule S, Nadir F, Taylor J & Costello C 1991 'Response to trans-retinoic acid in an AMLM3 patient resistant to cis-retinoic acid' Leukemia Research 15, (8) 765-765 , DOI
Rule S & Tucker D 0 'A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia' Therapeutics and Clinical Risk Management 979-979 , DOI
Dr Rule, Dr Furtado, Dr Furtado, Dr Rule & Rule 0 'Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin's Lymphoma: Focus on Brentuximab Vedotin' Clinical Medicine Insights: Oncology 31-31 , DOI
Letters
Forbes A, Farrell K, McKay P, Bolam S & Rule S 2013 'High dose cytarabine with rituximab is an effective first-line therapy for mantle cell lymphoma and produces ample stem cell harvest yields after multiple chemotherapy cycles' Leuk Lymphoma 54, (10) 2303-2305 Author Site , DOI
Shah N & Rule S 2013 'Rituximab administration in a community hospital environment' Leuk Lymphoma 54, (7) 1532-1533 Author Site , DOI
Conference Papers
Peggs K, Cook G, Russell N, Hunter A, Robinson S, Morley N, Sureda A, Smith P, Patrick P & Braganca N 2016 'Reduced Intensity Conditioning transplantation (RIC) as part of first line therapy for Mantle cell lymphoma: results from the Phase II Mini Allo trial (CRUK: C7627/A9080)' S69-S69
Hillmen P, Fraser G, Jones J, Rule S, O'Brien S, Dilhuydy MS, Jaeger U, Grosicki S, Cymbalista F & Sun S 2015 'Comparing Single-Agent Ibrutinib, Bendamustine Plus Rituximab (BR) and Ibrutinib Plus BR in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): An Indirect Comparison of the RESONATE and HELIOS Trials'
Tucker DL, Hasan M, Poplar S, Rockett M & Rule S 2015 'Does trans-cutaneous electrical nerve stimulation (TENS) alleviate the pain experienced during bone marrow sampling in addition to standard techniques? A randomised, double-blinded, controlled trial' 34-35
Cramer P, Chanan-Khan A, Demirkan F, Fraser G, Santucci Silva R, Pylypenko H, Grosicki S, Janssens A, Pristupa A & Mayer J 2015 'IBRUTINIB COMBINED WITH BENDAMUSTINE/RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): FIRST RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY' 55-56
Rule S, Jurczak W, Jerkeman M, Santucci R, Rusconi C, Trneny M, Offner F, Caballero D, Joao C & Witzens-Harig M 2015 'Ibrutinib Vs Temsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL)'
Trneny M, Lamy T, Walewski J, Belada D, Mayer J, Radford J, Jurczak W, Morschhauser F, Alexeeva J & Rule S 2015 'IMPACT OF PRIOR TREATMENT ON PFS FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS RANDOMIZED TO LENALIDOMIDE VS INVESTIGATOR'S CHOICE: A SUBGROUP ANALYSIS OF THE PHASE II MCL-002 (SPRINT) STUDY' 4-4
Cramer P, Chanan-Khan A, Fraser G, Demirkan F, Silva RS, Pylypenko H, Grosicki S, Janssens A, Goy A & Mayer J 2015 'Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)'
Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Pylypenko H, Grosicki S, Janssens A, Pristupa A & Goy A 2015 'Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab'
Hess G, Rule S, Jurczak W, Jerkeman M, Santucci R, Rusconi C, Caballero D, Joao CM, Witzens-Harig M & Bence-Bruckler I 2015 'Lymphoma Symptoms: Data from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL) Treated with Ibrutinib Vs. Temsirolimus'
Dyer MJS, Grigg A, Diaz MG, Dreyling M, Rule S, Lei G, Wassner-Fritsch E, Knapp A & Marlton P 2015 'Obinutuzumab (GA101) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or bendamustine for the first-line treatment of follicular non-Hodgkin lymphoma: final results from the maintenance phase of the phase Ib GAUDI study' 53-53
Rule S, Arcaini L, Walewski J, Skotnicki A, Belada D, Mayer J, Alexeeva J, Afanasyev B, Kuzmin A & Jurczak W 2015 'QUALITY OF LIFE IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS TREATED WITH LENALIDOMIDE VS INVESTIGATOR'S CHOICE: MCL-002 (SPRINT) TRIAL' 147-147
Shah NK, Richardson S & Rule S 2015 'Significant gender differences in the number and distribution of T cells in patients with mantle cell lymphoma' 54-55
Rule S, Goy A, Martin P, Ramchandren R, Alexeeva J, Popat R, Avivi I, Advani R, Le Gouill S & Horowitz N 2015 'Single-agent ibrutinib for the treatment of mantle cell lymphoma (MCL): evaluating the link between durable response and quality of life (QoL) in the SPARK study' 59-59
Trneny M, Lamy T, Walewski JA, Belada D, Mayer J, Radford JA, Jurczak W, Morschhauser F, Alexeeva J & Rule S 2015 'Subgroup analysis of the phase II randomized MCL-002 (SPRINT) study of lenalidomide vs investigator's choice in relapsed/refractory mantle cell lymphoma'
Fegan C, Bagshawe J, Salles G, Karlin L, Rule S, Shah N, Morschhauser F, Terriou L, Dyer M & Hutchinson C 2014 'A PHASE I STUDY OF THE ORAL BTK INHIBITOR ONO-4059 IN PATIENTS WITH RELAPSED/REFRACTORY AND HIGH RISK CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)' 250-250
Shah NK, Rule S, Salles G, Karlin L, Morschhauser F, Terriou L, Dyer M, Hutchinson C, Fegan C & Davison A 2014 'A phase I study of the oral Btk inhibitor ONO-4059 in patients with relapsed/refractory B-cell lymphoma' 57-58
Wang M, Goy A, Martin P, Ramchandren R, Alexeeva J, Popat R, Avivi I, Advani R, Le Gouill S & Horowitz N 2014 'Efficacy and Safety of Single-Agent Ibrutinib in Patients with Mantle Cell Lymphoma Who Progressed after Bortezomib Therapy'
Rule S, Briones J, Carella AM, Casasnovas O, Barreto WG, Pocock C, Osborne S, Smith R & Zaja F 2014 'Extending subcutaneous rituximab maintenance therapy from 2 years until progression versus observation in patients with indolent non-Hodgkin's lymphoma: interim safety data from the MABCUTE study' 67-68
Furtado MV, Shah NK & Rule SAJ 2014 'Fixed dose rituximab for diffuse large B cell lymphoma treated with R-CHOP - a retrospective audit' 56-56
Furtado MV, Munneke B, Wang M, Beaupre D, McGreivy J & Rule S 2014 'Ibrutinib associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma' 64-64
Dyer MJS, Grigg AP, Gonzalez Diaz M, Dreyling M, Rule S, Lei G, Wassner-Fritsch E, Fingerle-Rowson G & Marlton PV 2014 'Obinutuzumab (GA101) in Combination with CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) or Bendamustine for the First-Line Treatment of Follicular Non-Hodgkin Lymphoma: Final Results from the Maintenance Phase of the Phase Ib GAUDI Study'
Hillmen P, Pettitt A, Schuh A, Milligan D, Bowles K, Bareford D, Riaz JM, Follows G, Rule S & Wallis J 2014 'Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-adopted)' 19-20
Rule S, Wang ML, Martin P, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera J, Williams M & Barrientos JC 2014 'PHASE 2 STUDY OF IBRUTINIB IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: UPDATED SAFETY ANALYSIS ON PREVALENCE OF INFECTION, DIARRHEA, AND BLEEDING OVER TIME' 150-150
Tucker DL, Rogers B, Court N & Rule SA 2014 'Primary prophylaxis with G-CSF is unnecessary to maintain dose intensity and prevent unplanned hospitalisations and treatment delays. A two year retrospective cohort study of R-CHOP21 for diffuse large B-cell lymphoma in a regional tertiary referral unit' 52-52
Shah NK, Furtado M, Crosbie N & Rule S 2014 'Single centre outcome of mantle cell lymphoma over the past decade' 57-57
Townsend W, Kirkwood A, Patel A, Smith P & Rule S 2014 'Systemic treatment of relapsed mantle cell lymphoma after initial treatment with fludarabine and cyclophosphamide with or without rituximab: long-term follow-up of a large randomised trial' 66-66
Fegan C, Bagshawe J, Salles G, Karlin L, Rule S, Shah N, Morschhauser F, Terriou L, Dyer MJS & Walter H 2014 'The Bruton's Tyrosine Kinase (BTK) Inhibitor ONO-4059: Promising Single Agent Activity and Well Tolerated in Patients with High Risk Chronic Lymphocytic Leukaemia (CLL)'
Morschhauser F, Terriou L, Dyer M, Hutchinson C, Rule S, Shah N, Salles G, Karlin L, Fegan C & Bagshawe J 2014 'THE BRUTON'S TYROSINE KINASE (BTK) INHIBITOR ONO-4059: PROMISING SINGLE AGENT ACTIVITY IN PATIENTS WITH RELAPSED AND REFRACTORY NHL' 150-150
Dyer M, Hutchinson C, Rule S, Shah N, Salles GA, Karlin L, Morschhauser F, Terriou L, Fegan C & Davison A 2014 'The Bruton's tyrosine kinase (BTK) inhibitor ONO-4059: Single-agent activity in patients with relapsed and refractory non-GCB-DLBCL'
Wang M, Gordon LI, Rule S, Goy A, Hermine O, Rizo A, Zhuang SH & Dreyling MH 2013 'A phase III study of ibrutinib in combination with bendamustine and rituximab (BR) in elderly patients with newly diagnosed mantle cell lymphoma (MCL)'
Furtado MV, Shah NK, Levoguer A, Harding S & Rule S 2012 'Abnormal serum free light chain ratio predicts inferior overall survival in mantle cell lymphoma' 46-47
Eve HE, Carey S, Richardson SJ, Heise CC, Mamidipudi V, Shi T, Radford JA, Auer RL, Bullard SH & Rule SAJ 2012 'Efficacy and safety of conventional-dose lenalidomide followed by low-dose maintenance lenalidomide for relapsed/refractory mantle cell lymphoma (MCL): updated results from a UK phase II study' 14-14
Forbes A, Rule S, Farrell K, McKay P, Bolam S & Kruger A 2012 'First line treatment of mantle cell lymphoma with high dose cytarabine and rituximab' 51-51
Furtado MV & Rule S 2012 'First UK experience of BTK inhibitor PCI-32765-dramatic responses in relapsed/refractory mantle cell lymphoma' 47-48
Furtado MV, Riordan R, Dyer MJS & Rule S 2012 'Interim analysis results of a phase II trial of single agent ofatumumab in the treatment of relapsed/refractory mantle cell lymphoma' 47-47
Wang M, Rule SA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JEE & McGreivy J 2012 'Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up'
Wang M, Rule SA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JEE & McGreivy J 2012 'Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up'
Dyer MJS, Grigg A, Gonzalez M, Dreyling M, Rule SA, Lei G, Wassner-Fritsch E, Wenger MK & Marlton P 2012 'Obinutuzumab (GA101) in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) or Bendamustine in Patients with Previously Untreated Follicular Lymphoma (FL): Results of the Phase Ib GAUDI Study (BO21000)'
Rule S, Smith P, Johnson P, Bolam S, Follows G, Gambell J, Hillmen P, Jack A, Johnson S & Kirkwood A 2012 'The addition of rituximab to fludarabine and cyclophosphamide (FC) improves overall survival in newly diagnosed mantle cell lymphoma (MCL): results of the randomised UK National Cancer Research Institute (NCRI) trial' 12-12
Giles JA, Moony J, Pearce A, Hunter HM, Smith S, Rule S, Pottinger B & Hamon MD 2011 'Automated peripheral blood haematopoietic progenitor cell anaylsis on the Sysmex XE2100 and prediction of peripheral blood stem cell harvest timing' S358-S358
Eve HE, Bullard SH & Rule SA 2011 'EFFICACY AND SAFETY OF CONVENTIONAL-DOSE LENALIDOMIDE FOLLOWED BY LOW-DOSE MAINTENANCE LENALIDOMIDE FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (MCL): RESULTS FROM A UK PHASE II STUDY' 222-222
Coiffier B, Li W, Henitz ED, Karkera JD, Favis R, Gaffney D, Shapiro A, Theocharous P, Elsayed YA & van de Velde H 2011 'Identification of Patient Subgroups Demonstrating Longer Progression-Free Survival (PFS) Benefit with Bortezomib-Rituximab Versus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma (FL): Biomarker Analyses of the Phase 3 LYM3001 Study' 122-122
Furtado M, Eve H & Rule S 2011 'LENALIDOMIDE TREATMENT - SAFE TO ADMINISTER TO CYTOPENIC PATIENTS' 222-222
Eve H, Carey S & Rule S 2011 'POSITIVE CORRELATION BETWEEN CIRCULATING NK CELLS AND DISEASE RESPONSE IN MANTLE CELL LYMPHOMA (MCL) TREATED WITH LENALIDOMIDE: FIRST IN VIVO DATA SUPPORTING NK-MEDIATED CYTOTOXICITY AS A MECHANISM OF ACTION' 198-198
Furtado M, Shah N, Eve H, Levoguer A, Harding S & Rule S 2011 'SERUM FREE LIGHT CHAIN RATIO - A POTENTIAL BIOMARKER FOR MANTLE CELL LYMPHOMA' 220-220
Rule S, Smith P, Johnson PW, Bolam S, Follows GA, Gambell J, Hillmen P, Jack A, Johnson SAN & Kirkwood A 2011 'The Addition of Rituximab to Fludarabine and Cyclophosphamide (FC) Improves Overall Survival in Newly Diagnosed Mantle Cell Lymphoma (MCL): Results of the Randomised UK National Cancer Research Institute (NCRI) Trial' 202-203
Wang L, Martin P, Blum KA, Kahl BS, Maeda LS, Advani R, Williams ME, Rule S, Rodriguez S & Pang C-F 2011 'The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial' 203-204
Coiffier B, Osmanov E, Hong X, Scheliga A, Mayer J, Offner FC, Rule SA, Teixeira A, Walewski JA & Crump M 2010 'A Phase 3 Trial Comparing Bortezomib Plus Rituximab with Rituximab Alone In Patients with Relapsed, Rituximab-Naive or -Sensitive, Follicular Lymphoma' 373-374
Ngu LSP, Hyatt N, Eccleston T, Copplestone JA, Eve H, Rule SA & Thomas DW 2010 'Basal tissue factor levels are higher in patients with mantle cell lymphoma prior to lenalidamide therapy compared to controls' 39-39
Eve E, Richardson J & Rule S 2010 'DOWNREGULATION OF CD19, CD20 AND CD22 SURFACE EXPRESSION ON MANTLE CELL LYMPHOMA BY LENALIDOMIDE' 608-609
Hellmann A, Rule SA, Walewski J, Shpilberg O, Feng H, van de Velde H, Patel H, Skee DM, Girgis S & Louw V 2010 'Effect of the Cytochrome P450 3A4 Inducers, Rifampicin and Dexamethasone, on the Pharmacokinetic, Pharmacodynamic and Safety Profile of Bortezomib In Patients with Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL)' 1624-1624
Eve HE, Bullard SH & Rule SAJ 2010 'Efficacy and safety of single-agent lenalidomide for relapsed/refractory mantle cell lymphoma (MCL): Preliminary results from a UK-based open-label phase II trial' 42-43
Miles OA, Eve HE, Riordan RD & Rule SA 2010 'Orbital relapse of mantle cell lymphoma and response to novel treatment regimens' 44-44
Ngu LSP, Hyatt N, Caveen C, Copplestone JA, Eve H, Rule SA & Thomas DW 2010 'Use of the thrombin generation assay (calibrated automated thrombogram) in patients with multiple myeloma and mantle cell lymphoma on thalidomide or lenalidamide therapy' 38-39
Rule S, Smith P, Qian W, Gambell J, Curtis N, Johnson P & Linch D 2009 'Application of the mantle international prognostic index (MIPI) to patients with mantle cell lymphoma treated with fludarabine/cyclophosphamide: Results from a UK NCRI Lymphoma Group study'
Eve H, Determann O, Klapper W, Smith P, Qian W & Rule S 2009 'Ki-67 does not predict survival in newly-diagnosed mantle cell lymphoma treated with fludarabine and cyclophosphamide (FC) with or without rituximab (R)' 87-87
Eve H, Bullard S & Rule S 2009 'Preliminary toxicity results from a phase II trial of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy with or without Bortezomib for mantle cell lymphoma in first relapse' 12-12
Pace E, Dennison S, Morris J, Rule S, Pritchard C, Barton A & Loving J 2007 'A randomised crossover study of a nurse-led chemotherapy outreach project' 462-462 , DOI
Pace E, Dennison S, Morris J, Rule S, Pritchard C, Barton A & Loving J 2007 'A study to compare patient satisfaction with location of chemotherapy: community hospital versus cancer centre' 461-461 , DOI
Richardson SJ, Copplestone JA & Rule SAJ 2007 'CC-5013 (revlimid, lenalinomide) induces in vitro PBMC-toxicity against mantle cell lymphoma and this is enhanced by rituximab' 19-19
Eve HE & Rule SAJ 2007 'Impairment of peripheral blood stem cell mobilisation in patients with mantle cell lymphoma following primary treatment with fludarabine-based chemotherapy' 17-18
Oakervee H, Popat R, Hamblin M, Rule S, Rahemtulla A & Cavenagh J 2007 'Longterm follow up of T-VAD for untreated multiple myeloma' 177-178
Agathocleous A, Rule S, Johnson P, Radford JA, Lafon N, Hunter H, Kerr JP, Neeson SM, Matthews J & Strauss S 2007 'Preliminary results of a phase I/II study of weekly or twice weekly bortezomib in combination with rituximab, in patients with follicular lymphoma, mantle cell lymphoma and Waldenstrom's macroglobulinaemia' 754A-754A
Eve H, Smith P, Qian W, Stevens L & Rule S 2007 'Toxicity of fludarabine and cyclophosphamide (FC) +/- rituximab (R) as initial therapy for patients with previously-untreated mantle cell lymphoma: results of a randomised phase II study' 19-19
El-Najjar I, Rule SAJ & Nokes TJC 2006 'A fixed, low dose of anti-CD20 antibody (Rituximab) is an effective treatment for patients with chronic immune thrombocytopenia' 79-80
Rule S, Turner D, Smith S, Ewings P & Johnson S 2005 'A phase II study of S/C cladribine and oral cyclophosphamide in relapsed/refractory lymphoproliferative disorders' 204-205
Rule S, Burton C, Waleski J, Jack A & Seymour J 2005 'A randomised phase II study of fludarabine/cyclophosphamide +/-rituximab in patients with untreated mantle cell lymphoma' 95-95
Hunter HM & Rule SAJ 2005 'Rasburicase is effective in the prophylaxis of tumour lysis syndrome when used over a short duration in patients with haematological malignancy' 42-42
Hunter H & Rule S 2005 'Reduced course rasburicase remains effective in the prophylaxis of tumour lysis syndrome in at risk patients with high grade non Hodgkins lymphoma' 211-211
Harries LW, Wickham CL, Rule SA, Joyner MV & Ellard S 2004 'Improved quantitation of haematopoietic chimaerism by real-time polymerase chain reaction' 39-39
Duckworth AW, Farrugia J, Copplestone A, Prentice AG & Rule SAJ 2002 'Cyclin D1 mRNA transcript quantification in peripheral blood of mantle cell lymphoma patients - A robust diagnostic test' 280B-280B